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Distinct Clinical and Pathological Features Are
Associated with the BRAFT1799A(V600E) Mutation
in Primary Melanoma
Wendy Liu1,2,3, John W. Kelly2, Melanie Trivett1, William K. Murray1, John P. Dowling2, Rory Wolfe4,
Graham Mason5, Jill Magee6, Christopher Angel7, Alexander Dobrovic1 and Grant A. McArthur1,3
The BRAFT1799A mutation encodes BRAFV600E that leads to activation of the mitogen-activated protein kinase
pathway. This study aimed to assess the clinico-pathological features of primary invasive melanomas containing
the BRAFT1799A mutation. Patients (n¼ 251) with invasive primary melanomas from Australia were interviewed
and examined with respect to their melanoma characteristics and risk factors. Independent review of pathology,
allele-specific PCR for the BRAFT1799A mutation, immunohistochemical staining with Ki67, and phospho-histone-
H3 (PH3) were performed. The BRAFT1799A mutation was found in 112 (45%) of the primary melanomas.
Associations with the BRAFT1799A mutation (Po0.05) were as follows: low tumor thickness (odds ratio (OR)¼ 3.3);
low mitotic rate (OR¼ 2.0); low Ki67 score (OR¼ 5.0); low PH3 score (OR¼ 3.3); superficial spreading melanoma
(OR¼ 10.0); pigmented melanoma (OR¼ 3.7); a lack of history of solar keratoses (OR¼ 2.7); a location on the
trunk (OR¼ 3.4) or extremity (OR¼ 2.0); a high level of self-reported childhood sun exposure (OR¼ 2.0); p50
years of age (OR¼ 2.5); and fewer freckles (OR¼ 2.5). We conclude that the BRAFT1799A mutation has associations
with host phenotype, tumor location, and pigmentation. Although implicated in the control of the cell cycle, the
BRAFT1799A mutation is associated with a lower rate of tumor proliferation.
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INTRODUCTION
The BRAF proto-oncogene encodes the BRAF kinase, which
is a member of the RAF family of serine/threonine cyto-
plasmic kinases. The RAF kinases are part of the mito-
genic-activated protein kinase (MAPK) pathway, which is a
RAS activated protein kinase cascade involved in the control
of cell growth, proliferation, and differentiation (Robinson
and Cobb, 1997).
The high incidence of BRAF mutations throughout
melanoma progression suggests that BRAF may be an
attractive therapeutic target (Karasarides et al., 2004; Sharkey
et al., 2004; Sumimoto et al., 2004). Despite a large number
of studies, the clinical and pathologic associations of the
BRAFT1799A mutation in primary human melanoma remain
poorly understood. A better understanding of the biological
role of BRAF in human melanoma will assist in evaluating this
oncogene as a therapeutic target. The aim of this study was to
examine the clinical and pathological associations of the
BRAFT1799A mutation in invasive primary melanoma.
RESULTS
A total of 251 patients with invasive primary melanomas
were included in the final analyses. The male to female ratio
was 1.4. The median and mean ages were 56 and 55 years,
respectively (range 7–91 years). The median and mean tumor
thicknesses were 1.1 and 2.1 mm, respectively (range
0.1–18 mm). The BRAFT1799A mutation was found in 112
(45%) of the primary melanomas. Of the 251 patients with
BRAF status available, 209 patients had sufficient tumor
tissue to perform immunohistochemical staining with Ki67
and phospho-histone-H3 (PH3).
BRAF and rate of tumor proliferation
The percentage of melanomas with the BRAFT1799A mutation
decreased with increasing tumor thickness (Ptrend, a test of
trend for ordered categories¼ 0.001) and mitotic rate
(Ptrend¼ 0.038). A total of 55% of tumors that were o1 mm
in Breslow thickness contained the BRAFT1799A mutation,
whereas only 27% of those X4 mm contained the mutation.
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A total of 53.9% of tumors that were less mitotically active
(o1/mm2) contained the BRAFT1799A mutation, compared to
a mutation frequency of 35.5% among tumors that were
highly mitotically active (X10/mm2). To further examine the
relationship between the BRAFT1799A mutation and cell
proliferation, staining with PH3 (a sensitive marker of mitosis
(Goto et al., 1999)) and Ki67 (a marker of actively cycling
cells (Gerdes et al., 1984)) was performed. The rate of
BRAFT1799A mutation decreased with increasing PH3
(Ptrend¼ 0.031) and Ki67 labelling (Ptrend¼ 0.026). An exam-
ple of staining for PH3 in a primary melanoma with a high
mitotic count is shown in Figure S1.
Clinical associations of BRAF
When compared to superficial spreading melanoma, the
frequency of the BRAFT1799A mutation was lower among
nodular melanomas (superficial spreading melanoma,
55.3%; nodular melanoma, 39.1%; P¼ 0.055) and lowest
among lentigo maligna melanoma (15.4%, P¼ 0.001). No
acral lentiginous melanomas (n¼ 6) or desmoplastic mela-
nomas (n¼ 7) harbored the BRAFT1799A mutation.
Tumor pigmentation was also strongly associated with the
BRAFT1799A mutation (P¼0.001). There was a substantial
level of agreement (Landis and Koch, 1977) between the
presence of pigmentation as assessed by macroscopic
assessment of the pathology specimen and the presence of
pigmentation as detected by patient (k¼ 0.61) and both
correlated with the presence of the BRAFT1799A mutation
(P¼0.001).
The BRAFT1799A mutation occurred more frequently
among patients who were 50 years of age or younger when
compared to those over 50 years (Po0.001). Melanomas
from patients with few freckles more frequently had the
BRAFT1799A mutation than those with moderate number of
freckles (P¼0.002) (Table 1).
The BRAFT1799A mutation in melanomas was negatively
associated with a history of solar keratoses (Po0.001) and posi-
tively associated with melanomas arising on intermittently
Table 1. Associations of the BRAFT1799A mutation
n T1799A WT % T1799A % WT OR 95% CI P Ptrend
Thickness
o1 mm 120 66 54 55.0 45.0 —
1–4 mm 94 36 58 38.3 61.7 0.5 0.3, 0.9 0.016
44 mm 37 10 27 27.0 73.0 0.3 0.1, 0.7 0.004 0.001
Mitosis
o1/mm2 104 56 48 53.9 45.2 —
1–4/mm2 86 33 53 38.4 61.6 0.5 0.3, 1.0 0.034
5–9/mm2 30 12 18 40.0 60.0 0.6 0.2, 1.3 0.184
X10/mm2 31 11 20 35.5 64.5 0.5 0.2, 1.0 0.076 0.038
Ph3
o1/mm2 63 33 30 52.4 47.6 —
1–4/mm2 65 34 31 52.3 47.7 1.0 0.5, 2.0 0.993
5–9/mm2 26 10 16 38.5 61.5 0.6 0.2, 1.4 0.235
10–20/mm2 25 6 19 24.0 76.0 0.3 0.1, 0.8 0.019
420/mm2 30 12 18 40.0 60.0 0.6 0.3, 1.5 0.266 0.031
Ki67
p10% 131 68 63 51.9 48.1 —
11–20% 32 11 21 34.4 65.6 0.5 0.2, 1.1 0.079
21–40% 27 12 15 44.4 55.6 0.7 0.3, 1.7 0.481
440% 19 4 15 21.1 78.9 0.2 0.1, 0.8 0.018 0.026
Type
SSM 161 89 72 55.3 44.7 —
NM 46 18 28 39.1 60.9 0.5 0.3, 1.0 0.055
LMM 26 4 22 15.4 84.6 0.1 0.0, 0.4 0.001 o0.001*
ALM 6 0 6 0.0 100.0
DM 7 0 7 0.0 100.0
Others 5 1 4 20.0 80.0
Table 1 continued on the following page
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sun-exposed sites (trunk, odds ratio (OR)¼ 3.4, P¼0.001;
extremities, OR¼2.0, P¼ 0.051).
A high level of self-reported childhood sun exposure was
associated with melanomas harboring the BRAFT1799A muta-
tion (48.0 vs 31.0%, P¼ 0.047).
Although mutations in BRAF are found in a high
proportion of melanocytic nevi (Pollock et al., 2003), the
BRAFT1799A mutation was associated with neither the total
number of melanocytic nevi (P¼ 0.499), nor the number of
dysplastic nevi (P¼ 0.527) as assessed by clinical examina-
tion in our patient cohort. The BRAFT1799A mutation was not
associated with a history of melanoma (P¼0.641) or a family
history of melanoma (P¼ 0.402). Other clinical variables
assessed that were not associated with the BRAFT1799A
mutation were: the presence of ulceration on histology,
gender, skin phototype, eye color, degrees of solar lentigines,
a history of blistering sunburns, self-reported level of
recreational or occupational sun exposure.
Multivariate analyses
In a multivariate model, fewer freckles (OR¼ 5.0, P¼0.004),
pigmented melanomas (OR¼ 8.6, P¼ 0.013), a lack of
history of solar keratoses (OR¼4.2, P¼ 0.012), a location
on the trunk (OR¼9.0, P¼ 0.004), a location on the
extremity (OR¼6.2, P¼0.013), and a high level of self-
reported childhood sun exposure (OR¼5.0, P¼0.020) were
found to independently associate with melanomas containing
the BRAFT1799A mutation (Table 2).
DISCUSSION
Findings from our study suggest that the BRAFT1799A mutation
is associated with distinct clinical, phenotypic, and patho-
logical features. The data demonstrated that fewer freckles,
pigmented melanomas, a location on the trunk or extremity, a
lack of history of solar keratoses are independently associated
with the BRAFT1799A mutation, as well as melanomas with
lower thickness and lower rate of proliferation.
Table 1. continued
n T1799A WT % T1799A % WT OR 95% CI P Ptrend
Amelanosis
Yes 46 10 36 21.7 78.3 —
No 183 93 90 50.8 49.2 3.7 1.7, 7.9 0.001
Age
p50 92 55 37 59.8 40.2 —
450 159 57 102 35.9 64.1 0.4 0.2, 0.6 o0.001
Freckles1
Few 55 30 25 54.6 45.4 —
Moderate 42 13 29 30.9 69.1 0.4 0.2, 0.9 0.002
Many 23 10 13 43.5 56.5 0.6 0.2, 1.7 0.374 0.159
History of solar keratoses
Yes 89 27 62 30.3 69.7 —
No 156 84 72 53.9 46.1 2.7 1.5, 4.6 o0.001
Sites
Head and neck 58 17 41 29.3 70.7 —
Trunk 84 49 35 58.3 41.7 3.4 1.7, 6.9 0.001
Extremities 102 46 56 45.1 54.9 2.0 1.0, 3.9 0.051 0.003*
Volar/subungual 7 0 7 0.0 100.0
Self-reported childhood sun exposure
High 196 94 102 48.0 52.0 —
Low 42 13 29 31.0 69.0 0.5 0.2, 1.0 0.047
ALM, acral lentiginous melanoma; CI, confidence interval; DM, desmoplastic melanoma; LMM, lentigo maligna melanoma; n, number; NM, nodular
melanoma; OR, odds ratio; P, P-value; PH3, phospho-histone-H3; Ptrend, P-value for test of trend; SSM, superficial spreading melanoma; T1799A,
BRAFT1799A; WT, BRAFwild-type.
*Unordered categories hence P-value is for the global test of all pairwise comparisons of categories.
1Examined patients only (n=125).
—, reference point.
Note: variation in total numbers of patients in each category is due to some data being unobtainable.
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A novel finding derived from our study was that fewer
freckles were independently associated with the BRAFT1799A
mutation. The term freckle used here refer to ephelides, a
clinical entity characterized by multiple small, pale brown
macular lesions that occur in fair skinned individual that
darken with sun exposure and fade with sun protection.
Freckles are known to associate with sun sensitivity
(Bastiaens et al., 1999) and the presence of melanocortin-1-
receptor variants (Bastiaens et al., 2001). We speculate that
there may be an interaction between the melanocyte-
stimulating hormone–melanocortin-1-receptor pathway and
the RAS–RAF–MAPK pathway, through mediators such as
cAMP (Busca et al., 2000).
The pattern of sun exposure was associated with
melanomas containing the BRAFT1799A mutation. Markers of
cumulative sun exposure, including a history of solar
keratoses and the location on the head and neck, were both
found to be inversely related to the BRAFT1799A mutation.
Solar keratoses are considered as a personal indicator of
cumulative sun exposure (Frost and Green, 1994; Kennedy
et al., 2003). These inverse associations with the BRAFT1799A
mutation argue against cumulative sun exposure being
important in the induction of BRAFT1799A mutation in
melanocytic cells. In contrast, the association between the
BRAFT1799A mutation and the intermittently sun exposed
body sites such as the trunk or extremities suggests that
intense UV exposure on sun-sensitive skin may contribute to
the DNA damage in the skin and to the development of the
BRAFT1799A mutation. Our findings were consistent with
previous findings of Maldonado et al. (2003) and in this
respect, support the hypothesis of a ‘‘dual pathway’’ to
melanoma genesis (Rivers, 2004).
Another novel finding from this study was the association
of the BRAFT1799A mutation with tumor pigmentation.
Pigmentation in a melanoma is related to the amount of
melanin production. Melanin is produced from the amino
acid tyrosine by a biosynthetic pathway that includes the
enzyme tyrosinase. One of the key regulators of tyrosinase
production is microphthalmia-associated transcription factor
(MITF) (Goding, 2000). MITF is critical for melanocyte
lineage commitment (Widlund and Fisher, 2003) and is
considered essential for melanocyte survival (Tassabehji
et al., 1994). MITF activity is modulated by a number of
mechanisms (Goding, 2000), including the MAPK-dependent
phosphorylation (Hemesath et al., 1998). In our study, the
observation of more frequent pigment production in
primary melanomas containing the BRAFT1799A mutation
supports previous evidence of a close link between MAPK
and MITF in both cell culture and animal models (Hemesath
et al., 1998). Mutant BRAFV600E may activate the MAPK
pathway and modulate MITF function and melanocyte
differentiation.
It is interesting to note that the BRAFT1799A was
significantly correlated with favorable prognostic indicators
such as lower thickness (Ptrend¼0.001), lower mitotic rate
(Ptrend¼ 0.038), lower expression of the mitotic marker PH3
(Ptrend¼ 0.031), and lower expression of the cell proliferation
marker (Ki67, Ptrend¼0.026). This observation indicates that
BRAFT1799A, when compared to melanomas that are wild-
type for BRAF, may be associated with a more differentiated
form of melanoma with a slower cell proliferation rate.
Although considered an oncogene, RAF activation can also
induce cell senescence in non-immortalized human lung
fibroblasts (Zhu et al., 1998) and in melanocytic nevi
(Michaloglou et al., 2005). Moreover, a study has shown
that MITF functions downstream of BRAF to regulate
differentiation of melanocytes and can activate p21Cip1,
hypo-phosphorylate the retinoblastoma protein and drive
cells into senescence (Carreira et al., 2005). Therefore in
some contexts, activation of BRAF may promote differentia-
tion, senescence and reduced proliferation, providing one
possible explanation for the inverse relationship between the
BRAFV600E mutation and markers of aggressive melanoma.
In summary, this prospective study on the clinical and
pathologic associations of the BRAFT1799A mutation in
primary melanoma provided evidence of distinct associations
with host phenotype, environmental sun exposure pattern,
tumor histologic characteristics, and pigment production.
Although part of the MAPK pathway that regulates cell
proliferation, the BRAFT1799A was associated with lower
tumor thickness and lower rate of tumor proliferation.
Inhibition of BRAF in human melanoma, therefore,
may have additional biological affects to reduced cell
Table 2. The multivariate analyses of independent
associations of the BRAFT1799A mutation
Multivariate
OR 95% CI P
Amelanosis
Yes 1.0 —
No 8.6 1.6 46.6 0.013
Site
Head/neck 1.0 —
Trunk 9.0 2.0, 40.6 0.004
Extremities 6.2 1.5, 26.1 0.013
Self-reported childhood sun exposure
High 1.0
Low 0.2 0.0, 0.8 0.020
Freckles
Few 1.0 —
Moderate 0.2 0.0, 0.6 0.004
Many 0.5 0.1, 2.1 0.383
Solar keratoses
Yes 1.0 —
No 4.2 1.4, 13.0 0.012
CI, confidence interval; OR, odds ratio; P, P-value.
—, reference point.
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proliferation, such as induction of apoptosis, altered cell
motility or differentiation. Investigations into the genetic
changes in melanoma have suggested that a number of
proteins that interact with MAPK-pathway such as RAS, MITF,
phosphatase and tensin homolog deleted on chromosome
ten, retinoblastoma protein, cyclin-dependent kinase 4, and
cyclin D1 (Curtin et al., 2005) may play a role in melanoma
biology. Further studies of how these proteins relate to
mutations in the BRAF oncogene including examination of
clinicopathologic features will enhance our understanding of
their biological relevance and the rationale for targeted
therapy of melanoma.
MATERIALS AND METHODS
From May 2003 to September 2004, 251 patients with primary
cutaneous melanoma tissue available were recruited from two
tertiary melanoma referral centers in Melbourne. Study investiga-
tions were performed with adherence to the Declaration of Helsinki
Principles after approval by the local Human Research Ethics
Committees. Informed consent was obtained from all participants.
The age, gender, and the site of the melanoma for each patient were
recorded. An amelanotic melanoma as determined by pathology was
defined as a melanoma which lacked pigmentation, based on
macroscopic examination of the excised tissue by a pathologist.
All patients were interviewed by a medically trained study
investigator. The questions explored were as follows: a history of
melanoma, a family history of melanoma, a history of solar
keratoses, a history of blistering sunburn, skin phototypes, eye color,
and the pigmentary characteristics of the melanoma. Each patient
was asked to estimate his or her level of occupational, recreational
sun exposure and childhood sun exposure as high or low. An
amelanotic melanoma as recognized by patient was defined as a
melanoma that was predominantly pink, red, or white in color as
reported by the patient.
Those patients attending the Victorian Melanoma Service had
their skin examined by one of two dermatologists with respect to
total number of melanocytic nevi, number of clinically dysplastic
nevi, number of freckles, and solar lentigines. To look for potential
selection bias, we analyzed the characteristics of the examined
patients (n¼ 125) and non-examined patients (n¼ 126) and the
results were presented in the Table S1.
Independent review of pathology was performed on all speci-
mens with respect to: Breslow thickness, Clark’s level, ulceration,
mitotic rate, and tumor subtype (Clark et al., 1969).
Genomic DNA was extracted from paraffin-embedded tumor
tissue derived from microdissection, using a Qiagen DNeasy
extraction kit (Qiagen Ltd, Valencia, CA). All primary melanomas
were screened with duplex allele-specific-PCR for the BRAFT1799A
mutation using primers design and PCR conditions as outlined by
Pollock et al. (2003). Duplex allele-specific-PCRs were repeated in a
random subset of samples (n¼ 68, 27, 100% concordance). The
positive control used was DNA from the SKMEL28 cell lines and the
negative control used was DNA extracted from a blood sample of a
normal donor. Serial dilution tests of mixing DNA known to harbor
the BRAFT1799A mutation with control genomic DNA revealed that
the sensitivity of the allele-specific-PCR was 2%.
Sections were stained with a mAb to Ki67 (clone MIB1, 1:200
dilution, Dako, Glostrup, Denmark) to detect proliferating cells
(Gerdes et al., 1984) and a polyclonal antibody to PH3 (1:800
dilution, Upstate, Charlottsville, VA) to detect mitotic cells (Goto
et al., 1999). The antigens were unmasked by pressure cooking and
all incubations were performed at room temperature.
All slides were assessed independently by two investigators. The
Ki67 staining (% of staining cells in the dermis) and the PH3 staining
(numbers of staining cells/mm2 in the dermis) were assessed,
beginning in the most immunoreactive area. The interclass correla-
tions of the two independent assessors were 0.91 for PH3
scores (95% confidence interval¼ 0.89–0.93) and 0.89 for Ki67
(95% confidence interval¼ 0.87–0.92), indicating an excellent
degree of agreement (Fleiss, 1981). The final score of Ki67 and the
final score of PH3 were defined as the average of scores from the two
assessors.
Statistical analyses
Univariate logistic regression models were used to relate variables
with the presence of the BRAFT1799A mutation. For variables with
ordered categories, we performed tests of trend to assess whether
there was evidence of a constant increment in prevalence of the
BRAFT1799A mutation for each increasing category. Within the
logistic regression models, tests of trend were calculated by
considering ordered categories to have increasing integer scores
and analyzing the variable as though these were continuous. All
variables that had a significant (defined as Po0.05) likelihood-ratio
test on univariate analysis were entered into a multivariate logistic
regression model. A backward stepwise selection procedure based
on likelihood-ratio tests was used to select an optimal multivariate
logistic regression model.
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